Marshall Wace
ONCY

Marshall Wace’s Oncolytics Biotech ONCY Stock Holding History

Marshall Wace’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$731K Buy
859,831
+597,661
+228% +$594K ﹤0.01% 2284
2025
Q4 		$228K Sell
262,170
-61,812
-19% -$66.8K ﹤0.01% 2555
2025
Q3 		$454K Buy
+323,982
New +$363K ﹤0.01% 2268
2021
Q1 		– Sell
-112,594
Closed -$268K – 2756
2020
Q4 		$268K Buy
+112,594
New +$270K ﹤0.01% 1680

Other funds holding ONCY

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFP
Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace's ONCY Position: Q1 2026 in Review

Marshall Wace increased its Oncolytics Biotech (ONCY) stake by 228% in Q1 2026, buying an estimated $594K and bringing the position to 859,831 shares worth $731K. The position accounts for ﹤0.01% of the portfolio, ranked #2284.

Marshall Wace first reported a position in ONCY in Q4 2020 and has held it in 4 quarters since. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

  • Marshall Wace held 859,831 shares of Oncolytics Biotech worth $731K as of Q1 2026.
  • Marshall Wace bought 597,661 Oncolytics Biotech shares in Q1 2026, an estimated $594K.
  • Oncolytics Biotech made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2284 holding.
  • Marshall Wace first reported a position in Oncolytics Biotech in Q4 2020 and has held it in 4 quarters since.
  • 59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.